Autism Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : May 2019 |
  • Pages : 188 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Autism Spectrum Disorder Therapeutics Market – Insights

Autism Spectrum Disorder (ASD) is a neurodegenerative disorder, which is associated and often overlaps with other conditions such as epilepsy, frequent infections, sleep disorders, anxiety, depression, and gastrointestinal problems. ASD is only diagnosed by developmental and comprehensive tests. It can be detected at eighteen months to two years of age. Drugs such as Aripiprazole, Risperidone, and Melatonin are U.S. Food and Drug Administration (FDA) approved drugs that aid in the treatment of ASD. Bumetanide and Balovaptan are the drugs that are under clinical trial and investigation to evaluate their safety and efficacy for the treatment of ASD. 

The global autism spectrum disorder therapeutics (ASD) therapeutics market size was valued at US$ 2,169.3 million in 2018, and is expected to witness a CAGR of 6.8% over the forecast period (2018 – 2026).

Global Autism Spectrum Disorder Therapeutics Market Share (%) Analysis, By Drug Type, 2018

Source: Coherent Market Insights Analysis (2019)

Increasing Number of Pipeline Drugs and Early Diagnosis of ASD is expected to Drive Growth of the Autism Spectrum Disorder Therapeutics Market

Increasing number of pipeline drugs and launches of novel products by key players are expected to be the major driving factors for the global autism spectrum disorder therapeutics market growth during the forecast period. For instance, in February 2014, the company was awarded six new patents for its enzyme delivery system in Europe, Australia, and Central America, which can be utilized for multiple enzyme products including CM-AT— Curemark’s proprietary ASD drug.

Furthermore, in September 2017, Curemark conducted second Phase III clinical trial: Blüm Study— to evaluate the safety and efficacy of CM-AT in children aged 3-8 with ASD.

Moreover, earlier diagnosis of ASD can aid in the development of children. For instance, according to the research published in the JAMA Pediatrics journal in April 2019, accurate diagnosis of ASD at earlier than 18 months is feasible and there may be opportunities to test the usefulness of ASD treatment at an early age. Therefore, increasing research on ASD is expected to create a favorable environment for autism spectrum disorder therapeutics market growth over the forecast period.

Autism Spectrum Disorder Therapeutics Market - Restraints

Shortage of specialist doctors to diagnose ASD accurately is one of the major factors, which is expected to hamper the ASD therapeutics market. For instance, according to Simons Foundation Autism Research Initiative’s (SFARI) research, in 2018, there are only 8,300 child psychiatrists, 1,500 child neurologists, and 1,000 developmental-behavioral pediatricians for over 1 million autistic children in the U.S. The shortage of specialist doctors to diagnose ASD hampers growth of the ASD therapeutic market.

Autism Spectrum Disorder Therapeutics Market - Regional Insights

On the basis of region, the global autism spectrum disorder therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global autism spectrum disorder therapeutics market during the forecast period, owing to increasing prevalence of ASD in the pediatric population of the U.S. For instance, according to the Centers for Disease Control and Prevention’s (CDC) report released in April 2018, 1 in every 59 children was identified with ASD in the age range of 3 to 17 years in 2014.

Asia Pacific is expected to foresee a rapid growth in the autism spectrum disorder therapeutics market revenue. This is owing to increase in sales of Aripiprazole for the treatment of ASD. For instance, in 2017, Otsuka Pharmaceutical’s ABILIFY MAINTENA (Aripiprazole) generated US$ 62.9 million in revenue with a growth of 24.1% compared to the revenue in 2016. Moreover, ABILIFY accounted for a revenue of US$ 59.7 million in 2017.

Global Autism Spectrum Disorder Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%) 2016-2026

   

 Source: Coherent Market Insights Analysis (2019)

Autism Spectrum Disorder Therapeutics Market - Competitive Landscape

Key players operating in the global autism spectrum disorder therapeutics market include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb.

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. / Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study:

  • This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Autism Spectrum Disorder Therapeutics Market, By Drug Type:
    • Aripiprazole
    • Risperidone
    • Melatonin
    • CM-AT
    • Bumetanide
    • Balovaptan
  • Global Autism Spectrum Disorder Therapeutics Market, By Age Group:
    • Child
    • Adult
  • Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Autism Spectrum Disorder Therapeutics Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Type:
        • Aripiprazole
        • Risperidone
        • Melatonin
        • CM-AT
        • Bumetanide
        • Balovaptan
      • By Age Group:
        • Child
        • Adult
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Aripiprazole
        • Risperidone
        • Melatonin
        • CM-AT
        • Bumetanide
        • Balovaptan
      • By Age Group:
        • Child
        • Adult
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Aripiprazole
        • Risperidone
        • Melatonin
        • CM-AT
        • Bumetanide
        • Balovaptan
      • By Age Group:
        • Child
        • Adult
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Aripiprazole
        • Risperidone
        • Melatonin
        • CM-AT
        • Bumetanide
        • Balovaptan
      • By Age Group:
        • Child
        • Adult
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Aripiprazole
        • Risperidone
        • Melatonin
        • CM-AT
        • Bumetanide
        • Balovaptan
      • By Age Group:
        • Child
        • Adult
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Aripiprazole
        • Risperidone
        • Melatonin
        • CM-AT
        • Bumetanide
        • Balovaptan
      • By Age Group:
        • Child
        • Adult
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • F. Hoffmann-La Roche AG.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Neurim Pharmaceuticals, Inc.
    • Yamo Pharmaceuticals LLC
    • Servier Laboratories Ltd.
    • Otsuka Holdings Co. Ltd.
    • Curemark LLC
    • Oryzon Genomics S.A.
    • GW Pharmaceuticals Plc.
    • Teva Pharmaceutical Industries Ltd.
    • Zynerba Pharmaceuticals Inc.
    • Stalicla SA.
    • Novartis AG
    • Pfizer, Inc.
    • Bristol Myers Squibb.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Age Group
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Landscape
    • Collaborations & Partnerships
    • Epidemiology Analysis
    • Pipeline Analysis & Approved Product Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • Porter’s Five Forces model
  4. Global Autism Spectrum Disorder Therapeutics Market, By Drug Type, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Aripiprazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Risperidone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Melatonin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • CM-AT
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Bumetanide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Balovaptan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
  5. Global Autism Spectrum Disorder Therapeutics Market, By Age Group, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Child
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Adult
      • Introduction  
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
  6. Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction  
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
  7. Global Autism Spectrum Disorder Therapeutics Market, By Region, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2018 – 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Age Group, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Neurim Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Yamo Pharmaceuticals LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Servier Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Otsuka Holdings Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Curemark LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Oryzon Genomics S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GW Pharmaceuticals Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zynerba Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • STALICLA SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bristol Myers Squibb
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 38 market data tables and 27 figures on "Autism Spectrum Disorder Therapeutics Market” - Global forecast to 2026”

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.